Everything below concerns REV-ERB. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-01-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
=== Moisture balance === Establishing a moisture balance beneficial to the wound bed is another prerequisite of care. The natural response to injury is inflammation typified by the local expression of histamine and bradykinin and leading to vasodilation of the vessels that are in relative close proximity to the site of injury. As serum based fluid moves out of the vessels into the interstitial spaces the resultant soft tissue oedema manifests on the wound surface as exudate. In the chronic wound this exudate contains a surfeit of proteolytic enzymes and other components not seen in acute wounds and these compounds have a corrosive effect on the wound bed and surrounding peri-wound skin. The application of dressings, topical negative pressure, compression garments and leg elevation/exercise have been identified as methods for management of wound exudate.
=== Aviation === In 2023, Transworld Group expanded into the aviation sector with its luxury private jet charter service, Airavat, operating in the Middle East, Europe, and Asia. In 2024, Transworld Group entered into a joint venture with former SpiceJet COO Arun Kashyap's Sirius India Airlines to begin operations in India.
=== Bulk foams and aerogels === Nanocellulose can also be used to make aerogels/foams, either homogeneously or in composite formulations. Nanocellulose-based foams are being studied for packaging applications in order to replace polystyrene-based foams. Svagan et al. showed that nanocellulose has the ability to reinforce starch foams by using a freeze-drying technique. The advantage of using nanocellulose instead of wood-based pulp fibers is that the nanofibrils can reinforce the thin cells in the starch foam. Moreover, it is possible to prepare pure nanocellulose aerogels applying various freeze-drying and super critical CO2 drying techniques. Aerogels and foams can be used as porous templates. Tough ultra-high porosity foams prepared from cellulose I nanofibril suspensions were studied by Sehaqui et al. a wide range of mechanical properties including compression was obtained by controlling density and nanofibril interaction in the foams. CNCs could also be made to gel in water under low power sonication giving rise to aerogels with the highest reported surface area (>600m2/g) and lowest shrinkage during drying (6.5%) of cellulose aerogels. In another study by Aulin et al., the formation of structured porous aerogels of nanocellulose by freeze-drying was demonstrated. The density and surface texture of the aerogels was tuned by selecting the concentration of the nanocellulose dispersions before freeze-drying. Chemical vapour deposition of a fluorinated silane was used to uniformly coat the aerogel to tune their wetting properties towards non-polar liquids/oils.
Perfectionism identifies well-being with excellence by fulfilling human nature. It holds that one needs to exercise and master key human abilities, such as rationality, knowledge, health, and dignity, to live well. As an objectivist perspective, perfectionism asserts that the value of these goods does not depend on what a person thinks about them. Eudaimonism is a closely related view, asserting that someone has high well-being or flourishes in life by actualizing their inborn potential. This view emphasizes that well-being is not a passive state but an active process. It manifests in an engaged lifestyle where individuals exercise virtues and rely on practical rationality to guide their decision-making. Value fulfillment theories see the satisfaction of evaluative attitudes as the basis of well-being. They are similar to desire theories, which focus on desire satisfaction. However, value fulfillment theories adopt a broader perspective that considers diverse evaluative attitudes in addition to desires, such as beliefs, feelings, and judgments about what is good. Most theories assume that the definition of well-being applies equally to everyone. Variabilism rejects this assumption and argues that different conceptions of well-being apply to different individuals. One form of variabilism asserts that the nature of well-being in children differs from that of adults.
Sources: en.wikipedia.org
Heroin for the purposes of pain relief involves administration using a syringe with a nebulizer tip by a physician. Heroin may be used for fractures, burns, finger-tip injuries, suturing, and wound re-dressing, but is inappropriate in head injuries.
=== Sector zoning === Sector zoning is also associated with the crystallization of monazite in a melt. However, some elements may have a tendency to crystallize onto a specific crystal face. This results in uneven growth and composition.
== Mechanism of action == Binding to VEGF receptor induces dimerization, which modifies the conformation in the intracellular domain. This modification leads to the exposure of the ATP-binding site, which causes ATP binding on the receptor and also transphosphorylation on specific tyrosine residues. Tyrosine phosphorylation on the receptor is regulated by internalization, degradation and by dephosphorylation through different protein tyrosine phosphatases. This can then lead to the initial receptor signal transduction cascade, which activates several downstream enzymatic pathways. The signaling inhibition of VEGFR is through tumor vessels and not the tumor cells. Reduction of VEGF expression reduces blood flow to tumor and stops tumor angiogenesis.
=== Worldwide prevalences === BED is not something only to be found in Western countries. Evidence of increasing eating disorder prevalence has been observed in "non-Western countries and among ethnic minorities". Though the research on binge eating disorders tends to be concentrated in North America, the disorder occurs across cultures. Increasing globalization has influenced the prevalence of eating disorders outside of the West. In the US, BED is present in 0.8% of male adults and 1.6% of female adults in a given year. The prevalence of BED is lower in Nordic countries compared to Europe in a study that included Finland, Sweden, Norway, and Iceland. The point prevalence ranged from 0.4 to 1.5 percent and the lifetime prevalence ranged from 0.7 to 5.8 percent for BED in women. In a study that included Argentina, Brazil, Chile, Colombia, Mexico, and Venezuela, the point prevalence for BED was 3.53 percent. Therefore, this particular study found that the prevalence for BED is higher in these Latin American countries compared to Western countries. The prevalence of BED in Europe ranges from <1 to 4 percent.
Although it varies for every type of cell proposed, as their cell membrane composition varies greatly, It has been seen that in general, silver nanoparticles with an average size of 10 nm or less show electronic effects that greatly increase their bactericidal activity. This could also be partly due to the fact that as particle size decreases, reactivity increases due to the surface area to volume ratio increasing. Silver nanoparticles have been shown to have synergistic antibacterial activity with commonly used antibiotics such as; penicillin G, ampicillin, erythromycin, clindamycin, and vancomycin against E. coli and S. aureus. Furthermore, synergistic antibacterial activity has been reported between silver nanoparticles and hydrogen peroxide causing this combination to exert significantly enhanced bactericidal effect against both Gram negative and Gram positive bacteria. This antibacterial synergy between silver nanoparticles and hydrogen peroxide can be possibly attributed to a Fenton-like reaction that generates highly reactive oxygen species such as hydroxyl radicals. Silver nanoparticles can prevent bacteria from growing on or adhering to the surface. This can be especially useful in surgical settings where all surfaces in contact with the patient must be sterile. Silver nanoparticles can be incorporated on many types of surfaces including metals, plastic, and glass. In medical equipment, it has been shown that silver nano particles lower the bacterial count on devices used compared to old techniques.
Sources: en.wikipedia.org
The first Soviet development of artillery rockets was in 1921 when the Soviet military sanctioned the Gas Dynamics Laboratory, a small research laboratory to explore solid-fuel rockets, led by Nikolai Tikhomirov, who had begun studying solid and liquid-fueled rockets in 1894, and obtained a patent in 1915 for "self-propelled aerial and water-surface mines. The first test-firing of a solid fuel rocket was carried out in 1928. Further development was carried out in the 1930s by the Group for the Study of Reactive Motion (GIRD), where Soviet rocket pioneers Sergey Korolev, Friedrich Zander, Mikhail Tikhonravov and Leonid Dushkin launched GIRD-X, the first Soviet liquid-fueled rocket in 1933. In 1933 the two design bureaus were combined into the Reactive Scientific Research Institute and produced the RP-318, the USSR's first rocket-powered aircraft and the RS-82 and RS-132 missiles, which became the basis for the Katyusha multiple rocket launcher, During the 1930s Soviet rocket technology was comparable to Germany's, but Joseph Stalin's Great Purge from 1936 to 1938 severely damaged its progress. In 1945 the Soviets captured several key Nazi German A-4 (V-2) rocket production facilities, and also gained the services of some German scientists and engineers related to the project. A-4s were assembled and studied and the experience derived from assembling and launching A4 rockets was directly applied to the Soviet copy, called the R-1, with NII-88 chief designer Sergei Korolev overseeing the R-1's development., The R-1 entered into service in the Soviet Army on 28 November 1950.
Pakistan provided support to Saudi Arabia during the Gulf War. Pakistan chose to remain neutral during Operation Decisive Storm, refraining from sending military support to Saudi Arabia in its offensive against Yemen. Instead, Pakistan aimed to play a proactive diplomatic role in resolving the crisis, which led to tensions between the two countries. In 2016, Pakistan mediated between Saudi Arabia and Iran following the execution of Shia cleric Nimr al-Nimr, with visits to both countries by then Prime Minister Nawaz Sharif and the Chief of Army Staff, Raheel Sharif. Pakistan provided refuge to millions of displaced Afghans after the Soviet invasion and supported the Afghan mujahideen in their efforts to expel Soviet forces from Afghanistan. After the Soviets withdrew, infighting erupted among Mujahideen factions over control of Afghanistan. Pakistan facilitated peace talks to help end the conflict. After four years of unresolved conflict between rival Mujahideen groups, Pakistan helped establish the Taliban as a stabilising force. Pakistan's support for the Sunni Taliban in Afghanistan challenged Shia-led Iran, which opposed a Taliban-controlled Afghanistan. Pakistan vigorously advocated for self-determination among Muslims globally. Its efforts in supporting independence movements in countries like Indonesia, Algeria, Tunisia, Morocco, and Eritrea fostered strong ties. Due to its support for Azerbaijan in the Nagorno-Karabakh conflict, Pakistan has not established diplomatic relations with Armenia.
Pharmacology can be applied within clinical sciences. Clinical pharmacology is the application of pharmacological methods and principles in the study of drugs in humans. An example of this is posology, which is the study of the dosage of medicines. Pharmacology is closely related to toxicology. Both pharmacology and toxicology are scientific disciplines that focus on understanding the properties and actions of chemicals. However, pharmacology emphasizes the therapeutic effects of chemicals, usually drugs or compounds that could become drugs, whereas toxicology is the study of chemical's adverse effects and risk assessment. Pharmacological knowledge is used to advise pharmacotherapy in medicine and pharmacy.
where De is the effective dose, B bioavailability and Da the administered dose. Therefore, if a drug has a bioavailability of 0.8 (or 80%) and it is administered in a dose of 100 mg, the equation will demonstrate the following:
The administration of reboxetine with food delayed the absorption rate by approximately 2 hours while not affecting the extent of absorption. The absolute bioavailability is approximately 94%. Plasma concentrations of reboxetine fell in one exponential phase (monoexponential) with a half-life of about 12 hours. Steady-state is seen within 5 days. Reboxetine is 97% protein bound in young people and 92% in the elderly and is distributed into total body water. Radioactivity excreted in the urine corresponds to 78% of the dose. Even though the drug is mainly unchanged in blood circulation (70% of total radioactivity, as the area under the concentration curve (AUC)), only about 10% of the dose is excreted unchanged in the urine. Reboxetine is almost fully metabolised after oral administration. The drug is mainly metabolised through o-dealkylation and oxidation of the morpholine ring and hydroxylation of the ethoxyphenoxy ring. In vitro studies indicate that the CYP450(3A4) enzyme is primarily responsible for the metabolism of reboxetine. The drug is available as a racemic compound. The RR enantiomer is 10 times less potent than the SS enantiomer. The SS enantiomer (more potent) has a plasma level that is two times lower than the urinary excretion. Elimination of reboxetine is mainly via hepatic metabolism (by cytochrome P450 3A4) with a mean terminal half-life of about 12 hours. No significant difference was observed in the terminal half-lives of the RR and SS diastereomers. About 10% of the dose of reboxetine is cleared renally.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.